MediPharm Labs Names Greg Hunter CEO as CFO Transition Continues

MediPharm Labs (LABS.TO ) announced on November 4, 2026 that its board had appointed Greg Hunter as chief executive officer and a director, effective that day, making permanent the leadership role he had held on an interim basis since January 2026. The decision establishes long-term leadership at the pharmaceutical company, which specializes in precision-based cannabinoids, while leaving its finance leadership in transition.

Hunter will remain chief financial officer until a successor is appointed and an orderly transition is completed. No successor or completion date was identified. His immediate mandate therefore combines the CEO position with responsibility for the finance function he has led since joining MediPharm in February 2021.

“Following a thorough evaluation process, the Board concluded that Mr. Hunter is well positioned to lead MediPharm into its next phase,” said Keith Strachan, chair of MediPharm’s board. Strachan credited Hunter with strengthening the company’s financial foundation, improving operational performance and advancing its commercial strategy. During his interim tenure, Hunter also worked with the leadership team to advance strategic priorities and strengthen execution across the organization.

How the Leadership Change Developed

The permanent appointment resolves the CEO question posed by MediPharm’s January 19, 2026 leadership announcement. David Pidduck stepped down as CEO effective January 23, 2026, and Hunter became interim CEO while retaining the CFO role as the board evaluated its long-term leadership plans. Pidduck remained on the board to support the transition. The January announcement credited his tenure with significant restructuring initiatives, improved profitability and integration of VIVO Cannabis following its April 2023 acquisition.

Hunter has more than 20 years of experience across healthcare, manufacturing and consumer businesses, including leadership roles at Johnson & Johnson (JNJ ) and Baxter. His MediPharm responsibilities have extended beyond finance to commercial execution, operational efficiency, mergers and acquisitions, and domestic and international expansion. “I am excited about the opportunities ahead and look forward to continuing to execute our plan to drive profitable growth, operational excellence and long-term value creation,” Hunter said.

The Business Hunter Inherits

The second-quarter results provide context for Hunter’s emphasis on profitable growth and execution. In its August 13, 2026 results release, MediPharm reported revenue of $10.0 million, up 11% sequentially, and adjusted EBITDA of $0.9 million, marking a second consecutive positive quarter on that measure. Adjusted EBITDA is a company-defined non-IFRS measure that adds back interest, taxes, depreciation and amortization, non-cash adjustments and other unusual or non-recurring items to net income or loss. MediPharm returned to positive net income after a $3.8 million net loss in the second quarter of 2025, while operating expenses fell 44% year over year to $4.0 million following restructuring completed in the first quarter of 2026.

International medical revenue reached $5.8 million, up 26% sequentially and representing 58% of total revenue. German revenue increased 45% sequentially and 33% year over year. Canadian medical cannabis revenue fell 23% sequentially to $2.3 million after Veterans Affairs Canada reduced its maximum per-gram reimbursement rate by 29%, effective April 1, 2026.

Hunter takes the permanent role after a quarter of improved profitability and international growth, but with domestic reimbursement pressure and two executive roles still combined. The appointment settles who leads MediPharm; the remaining test is completing the finance handoff while preserving international momentum and recent profitability as the Canadian medical business adjusts to lower reimbursement.